Eli Lilly's weight-loss drug projected to reach $60bn by 2030, Bank of America sets $1,000 price target.

Eli Lilly stock is expected to surge 29% over the next year as its weight-loss drug could reach $60 billion in sales by 2030, according to Bank of America. The bank set a street-high $1,000 price target for Eli Lilly, based on the potential of its GLP-1 weight-loss drug. The analysts believe that additional opportunities in heart disease, obstructive sleep apnea, and liver disease are vastly underappreciated.